by dyadic | Sep 13, 2022 | Press Releases
JUPITER, Fla., Sept. 13, 2022 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for...
by dyadic | Sep 8, 2022 | Press Releases
JUPITER, Fla., Sept. 08, 2022 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for...
by dyadic | Aug 10, 2022 | Press Releases
Submission of a Clinical Trial Application (CTA) with South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 study to support clinical safety of proteins produced from proprietary C1-cell protein production platform and demonstrate...
by dyadic | Jul 27, 2022 | Press Releases
JUPITER, Fla., July 27, 2022 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving,...
by dyadic | Jul 5, 2022 | Press Releases
JUPITER, Fla., July 05, 2022 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary and patented...
by dyadic | Jun 9, 2022 | Press Releases
JUPITER, Fla., June 09, 2022 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1 protein...
